[Federal Register Volume 74, Number 168 (Tuesday, September 1, 2009)]
[Notices]
[Pages 45215-45216]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E9-21037]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[30Day-09-09AF]


Agency Forms Undergoing Paperwork Reduction Act Review

    The Centers for Disease Control and Prevention (CDC) publishes a 
list of information collection requests under review by the Office of 
Management and Budget (OMB) in compliance with the Paperwork Reduction 
Act (44 U.S.C. Chapter 35). To request a copy of these requests, call 
the CDC Reports Clearance Officer at (404) 639-5960 or send an e-mail 
to [email protected]. Send written comments to CDC Desk Officer, Office of 
Management and Budget, Washington, DC or by fax to (202) 395-5806. 
Written comments should be received within 30 days of this notice.

Proposed Project

    Evaluation of Pharmacy Syringe Access Linked to HIV Testing for 
Injection Drug Users in New York City (Pharm-HIV)--New--National Center 
for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP), 
Centers for Disease Control and Prevention (CDC).

Background and Brief Description

    HIV continues to be one of the leading causes of illness and death 
in the US, among injection drug users who are at high risk of acquiring 
HIV infection. HIV testing may not be readily accessible to this 
population in areas where they frequent. The New York State Legislature 
established an Expanded Syringe Access Demonstration Program (ESAP) in 
2001 in New York City. ESAP makes sterile syringes available for 
injection drug users through participating pharmacies, in order to help 
reduce the burden of HIV. The regular contact between pharmacists and 
their injection-drug-using syringe customers through ESAP paves the way 
for pharmacies to act as access points to health and social services 
among IDU customers. The expansion of pharmacy services to include 
referrals for injection-drug-using syringe customers is based on the 
successes of ESAP, which provides many services beyond syringe 
exchange.
    The New York Academy of Medicine (NYAM) has access to the ESAP list 
of pharmacies. NYAM will identify 12 ESAP pharmacies in East Harlem, 
New York City that are situated within predefined target neighborhoods 
where there are high levels of injection drug use. NYAM study staff 
will screen the ESAP pharmacies for eligibility by calling down a 
randomly-ordered list of ESAP-registered pharmacies and enrolling 
pharmacies willing to participate in this study. NYAM anticipates that 
they will have to contact 24 ESAP-registered pharmacies in the first 
year of the project (one pharmacy staff member at each pharmacy) in 
order to identify the 12 that will participate in the study. 
Recruitment of pharmacies will occur only during the first year.
    At the 12 ESAP-registered pharmacies that join the study, over a 
three year period, 442 adult (age >=18 yrs) injection-drug-using 
syringe customers will

[[Page 45216]]

complete a brief quantitative interview after HIV referral or HIV 
testing is offered to them. HIV-seropositive injection-drug-using 
syringe customers who are identified during HIV testing will be 
immediately linked to social and medical services. Ten of the 12 ESAP 
Pharmacies will provide referrals to local HIV testing sites for their 
injection-drug-using syringe customers. At these ten pharmacies, 40 
adult pharmacy staff will be surveyed on pharmacy staff attitudes and 
behaviors regarding HIV testing and referral.
    The remaining two ESAP pharmacies will pilot test the feasibility 
of offering and performing HIV counseling and testing in the pharmacy 
for injection-drug-using syringe customers. At these two pharmacies, 8 
adult (age >=18 yrs) pharmacy staff members will be surveyed on 
pharmacy staff attitudes and behaviors regarding HIV testing and 
referral. At the 12 pharmacies, 12 pharmacy staff members (one from 
each pharmacy) will be surveyed monthly to track study progress and 
obstacles to completing the study. Twelve pharmacy staff members (one 
from each pharmacy) will complete a daily syringe sales and referral 
log.
    There is no cost to the injection drug using customers who provide 
information to this study other than their time. The total estimated 
annual burden hours are 496 hours.

                                       Estimate of Annualized Burden Table
----------------------------------------------------------------------------------------------------------------
                                                                                                      Average
                                                                      No. of          No. of        burden per
             Respondent                       Form name             respondents    responses per   response (in
                                                                                    respondent        hours)
----------------------------------------------------------------------------------------------------------------
Pharmacist.........................  Pharmacy telephone                        8               1           10/60
                                      screening and enrollment
                                      form.
Pharmacist and Pharmacy Technician.  Pharmacy staff baseline                  48               1           20/60
                                      survey.
Pharmacist and Pharmacy Technician.  Pharmacy staff six monthly               48               2           20/60
                                      survey.
Pharmacist and Pharmacy Technician.  Pharmacy staff exit survey.              48               1           20/60
Pharmacist.........................  Pharmacy staff monthly                   12              10           10/60
                                      survey.
Pharmacy Technician................  Syringe sales and referral               12             300            5/60
                                      log.
Syringe-customer study participant.  Pharmlink Participant                   221               1           30/60
                                      Baseline Survey.
----------------------------------------------------------------------------------------------------------------


    Dated: August 26, 2009.
Marilyn S. Radke,
Reports Clearance Officer, Centers for Disease Control and Prevention.
[FR Doc. E9-21037 Filed 8-31-09; 8:45 am]
BILLING CODE 4163-18-P